Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Files An 8-K Other Events
Item8.01
| Other Events. |
On June6, 2017, Inovio Pharmaceuticals, Inc. (the
Company) was notified by the U.S. Food
and Drug Administration (the FDA) that
the FDA had removed the clinical hold on the Companys proposed
phase 3 clinical program for its product candidate, VGX-3100, as
a potential treatment for HPV-related cervical pre-cancer.
On June8, 2017, the Company issued a press release announcing the
removal of the clinical hold and its commencement of clinical
trials as part of the Phase 3 program. The full text of the
Companys press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
ExhibitNumber |
Exhibit Description |
|
| 99.1 | Press Release, dated June8, 2017. |
About Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.
